Therapeutic vaccines in solid tumours: can they be harmful?

  title={Therapeutic vaccines in solid tumours: can they be harmful?},
  author={A. M. M. Eggermont},
  journal={European journal of cancer},
  volume={45 12},
Rosenberg and coworkers caused an uproar in the immunotherapy community when they stated in a position paper that despite great advances in the field of tumour immunology, optimism about the clinical application of therapeutic vaccines lacked justification. They argued that such optimism was based more on surrogate end-points, which lacked robustness, than on proof of anti-tumour effects [Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10… CONTINUE READING

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 27 extracted citations


Publications referenced by this paper.
Showing 1-10 of 28 references

EORTC18961: Postoperative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4 N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results

  • AM Eggermont, S Suciu, W Ruka
  • J Clin Oncol
  • 2008
1 Excerpt

Expression of defined genes identified by pretreatment tumour profiling: Association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031)

  • J Louahed, O Gruselle, S Gaulis
  • J Clin Oncol
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…